ClinicalTrials.gg
CompletedNCT02214121HESTIA 1Updated Dec 14, 2018Results posted

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

A Phase 2 interventional study of Ticagrelor Dose 1a + Dose 2a and Ticagrelor Dose 1b + Dose 2b in Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease, sponsored by AstraZeneca. Completed at 18 sites in 6 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-12-14.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
210th of 559
46 · median 31
Started
2014
with 35 others
Phase 2
161 of 733
23 open now
Registered
278th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 210th largest by enrollment of the 559 interventional ones that give a count, is one of 36 that started in 2014, is one of 161 in phase 2, and was the 278th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with sickle cell disease

Read the detailed description

This is a multicenter, open-label, dose-ranging study of ticagrelor followed by a double blind, placebo-controlled extension phase in paediatric patients with sickle cell disease (SCD).

Part A: Patients will be randomised 1:1 to receive one of two dosing schedules consisting of two single weight-adjusted doses of ticagrelor. Pharmacokinetic (PK) parameters and pharmacodynamic (PD) measurements will be determined following each dose. Platelet aggregation will be measured using the VerifyNow™ P2Y12 assay.

Following these 2 single doses, all patients will receive open-label one-week treatment with ticagrelor twice daily to determine tolerability prior to randomisation into Part B.

Part B: In this part patients will be randomised (2:1 ratio) to ticagrelor twice daily or placebo for a 4-week treatment phase.

During the study, patients will be followed for the occurrence of vaso-occlusive crisis (VOC) and for other disease manifestations such as daily pain, analgesic use and complications of SCD.

03

Conditions studied

  • Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease

Browse trials for

Keywords

  • sickle cell anemia
  • paediatric
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged ≥2 to \<18 years of age
  • Diagnosed with homozygous sickle cell (HbSS) or sickle beta-zero-thalassaemia (HbS/β0)

Exclusion criteria

Exclusion criteria

  • At risk for haemorrhagic or bradycardic events
  • Significant hepatic impairment
  • Renal failure requiring dialysis
  • Concomitant oral or intravenous therapy with strong (cytochrome) inhibitors, CYP3A4 substrates with narrow therapeutic indices, or strong CYP3A4 inducers.
  • Surgical procedure planned to occur during the study.
  • Patients who are currently pregnant or breastfeeding or planning to become pregnant during the study.
  • Patients who have known or to ticagrelor.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Other
    Ticagrelor Dose 1a + Dose 2a

    Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.

    Drug: Ticagrelor Dose 1a + Dose 2a

  • Other
    Ticagrelor Dose 1b + Dose 2b

    Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.

    Drug: Ticagrelor Dose 1b + Dose 2b

Interventions

  • DrugTicagrelor Dose 1a + Dose 2a

    Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.

  • DrugTicagrelor Dose 1b + Dose 2b

    Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.

06

What researchers measure

Primary outcomes

  1. P2Y12 Reaction Units (PRU) - Part A

    Time frame: PRU measurements are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14). Up to 8 hours post-dose (6 hours following protocol amendment) Visit 2 and 3, and up to 2 hours Visit 4.

  2. P2Y12 Reaction Units (PRU) - Part B

    Time frame: PRU measurements are taken after 4 weeks of double blind treatment at the end of Part B.

  3. Maximum Plasma Concentration (Cmax) - Part A

    Time frame: PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).

  4. Maximum Plasma Concentration (Cmax) - Part B

    Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.

  5. Area Under the Plasma Concentration Time Curve (AUC) - Part A

    The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.

    Time frame: PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).

  6. Area Under the Plasma Concentration Time Curve (AUC) - Part B

    The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.

    Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.

Secondary outcomes

  1. Assessment of Ticagrelor Concentration - Part A

    Time frame: In conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7), after repeated dosing at Visit 4 (Day 14). Up to 8h post-dose (6h following protocol amendment, no pre-dose) Visit 2 and 3, up to 2h Visit 4 (pre-dose, 1h added following amendment)

  2. Assessment of Ticagrelor Concentration - Part B

    Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.

  3. Assessment of AR-C124910XX Concentration - Part A

    AR-C124910XX is the active metabolite of Ticagrelor

    Time frame: In conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7), after repeated dosing at Visit 4 (Day 14). Up to 8h post-dose (6h following protocol amendment, no pre-dose) Visit 2 and 3, up to 2h Visit 4 (pre-dose, 1h added following amendment)

  4. Assessment of AR-C124910XX Concentration - Part B

    AR-C124910XX is the active metabolite of Ticagrelor

    Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.

  5. Oral Clearance (CL/F) - Part A

    The PK parameter presented were derived using a model based analysis and not from a non-compartmental (NCA) analysis.

    Time frame: PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).

  6. Oral Clearance (CL/F) - Part B

    The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.

    Time frame: PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.

  7. Number of Vaso-occlusive Crises - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  8. Number of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  9. Percentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  10. Percentage of Days With Pain (Age >=4) - Part B

    Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  11. Mean Intensity of Pain (Age >=4) - Part B

    Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  12. Percentage of Days of Analgesic Use (Age >= 4) - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  13. Percentage of Days of Opioid Analgesic Use (Age >=4) - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

  14. Percentage of Days of Absence From School or Work (Age >=6) - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

Other outcomes

  1. Haemorrhagic Events - Part A

    Time frame: From randomisation to Part A (week 0) through Visit 4 (week 2)

  2. Haemorrhagic Events - Part B

    Time frame: During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).

07

Results

Posted May 11, 2018

Participant flow

The study was conducted at 24 centres, in 6 countries. The first patient was enrolled to Part A of the study on 11 Sep 2014, and the last patient completed Part B of the study on 27 Feb 2017. Recruitment was stopped due to protocol amendment between 8 September 2015 and 1 June 2016.

Part A
Participant flow — Part A
MilestonePart A - TicagrelorPart B - TicagrelorPart B - Placebo
Started4600
Completed3900
Not completed700
Withdrew: Patient decision200
Withdrew: Dev. of study-specific withdrawal crit.400
Withdrew: Other100
Part B
Participant flow — Part B
MilestonePart A - TicagrelorPart B - TicagrelorPart B - Placebo
Started0178
Completed0147
Not completed031
Withdrew: Patient decision010
Withdrew: Dev. of study-specific withdrawal crit.020
Withdrew: Lost to follow-up001

Outcome measures

PrimaryP2Y12 Reaction Units (PRU) - Part A
Time frame:
PRU measurements are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14). Up to 8 hours post-dose (6 hours following protocol amendment) Visit 2 and 3, and up to 2 hours Visit 4.
Reported as:
Mean · P2Y12 reaction units
P2Y12 Reaction Units (PRU) - Part A
P2Y12 reaction unitsTicagrelor 0.125 mg/kgTicagrelor 0.75 mg/kgTicagrelor 0.375 mg/kgTicagrelor 0.563 mg/kgTicagrelor 1.125 mg/kgTicagrelor 2.25 mg/kgTicagrelor 0.125 mg/kg BidTicagrelor 0.563 mg/kg BidTicagrelor 0.75 mg/kg Bid
Pre-dose301.6 ± 46.55268.0 ± 35.95295.4 ± 42.30287.7 ± 34.35283.7 ± 36.88277.7 ± 39.36320 ± NA205.4 ± 53.22214.7 ± 48.71
2 hours post-dose278.2 ± 47.20138.4 ± 70.68229.0 ± 64.22176.2 ± 79.53128.9 ± 37.6879.9 ± 47.74271.2 ± 70.35102.0 ± 72.53152.0 ± 72.35
6 hours post-dose276.0 ± 75.43189.0 ± 69.84266.0 ± 57.98190.4 ± 47.78191.2 ± 57.59141.7 ± 69.58———
8 hours post-dose343.0 ± 38.13—318.3 ± 66.43318.0 ± NA—————
PrimaryP2Y12 Reaction Units (PRU) - Part B
Time frame:
PRU measurements are taken after 4 weeks of double blind treatment at the end of Part B.
Reported as:
Mean · P2Y12 reaction units
P2Y12 Reaction Units (PRU) - Part B
P2Y12 reaction unitsTicagrelor 0.125 mg/kg BidPlacebo
Pre-dose282.8 ± 19.26313.3 ± 20.13
2 hours post-dose259.6 ± 61.95217.3 ± 78.34
PrimaryMaximum Plasma Concentration (Cmax) - Part A
Time frame:
PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) - Part A
ng/mLTicagrelor 0.125 mg/kgTicagrelor 0.75 mg/kgTicagrelor 0.375 mg/kgTicagrelor 0.563 mg/kgTicagrelor 1.125 mg/kgTicagrelor 2.25 mg/kgTicagrelor 0.125 mg/kg BidTicagrelor 0.563 mg/kg BidTicagrelor 0.75 mg/kg Bid
Maximum Plasma Concentration (Cmax) - Part A15.240 ± 15.2709162.961 ± 84.923052.069 ± 34.411596.031 ± 51.4902269.174 ± 162.2147566.550 ± 225.944713.973 ± 15.3652111.367 ± 81.1597157.216 ± 114.8138
PrimaryMaximum Plasma Concentration (Cmax) - Part B
Time frame:
PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) - Part B
ng/mLTicagrelor 0.125 mg/kg Bid
Maximum Plasma Concentration (Cmax) - Part B16.394 ± 13.3671
PrimaryArea Under the Plasma Concentration Time Curve (AUC) - Part A

The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.

Time frame:
PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration Time Curve (AUC) - Part A
ng*h/mLTicagrelor 0.125 mg/kgTicagrelor 0.75 mg/kgTicagrelor 0.375 mg/kgTicagrelor 0.563 mg/kgTicagrelor 1.125 mg/kgTicagrelor 2.25 mg/kgTicagrelor 0.125 mg/kg BidTicagrelor 0.563 mg/kg BidTicagrelor 0.75 mg/kg Bid
Area Under the Plasma Concentration Time Curve (AUC) - Part A161.9 ± 72.241151.9 ± 308.39437.5 ± 262.24879.3 ± 236.121638.7 ± 521.802850.9 ± 1277.39161.9 ± 72.24913.5 ± 208.821022.4 ± 287.32
PrimaryArea Under the Plasma Concentration Time Curve (AUC) - Part B

The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.

Time frame:
PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration Time Curve (AUC) - Part B
ng*h/mLTicagrelor 0.125 mg/kg Bid
Area Under the Plasma Concentration Time Curve (AUC) - Part B160.6 ± 88.58
SecondaryAssessment of Ticagrelor Concentration - Part A
Time frame:
In conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7), after repeated dosing at Visit 4 (Day 14). Up to 8h post-dose (6h following protocol amendment, no pre-dose) Visit 2 and 3, up to 2h Visit 4 (pre-dose, 1h added following amendment)
Reported as:
Geometric mean · ng/mL
Assessment of Ticagrelor Concentration - Part A
ng/mLTicagrelor 0.125 mg/kgTicagrelor 0.75 mg/kgTicagrelor 0.375 mg/kgTicagrelor 0.563 mg/kgTicagrelor 1.125 mg/kgTicagrelor 2.25 mg/kgTicagrelor 0.125 mg/kg BidTicagrelor 0.563 mg/kg BidTicagrelor 0.75 mg/kg Bid
Pre-dose——————2.170 ± NA31.937 ± 48.650128.066 ± 27.1344
1 hour post-dose12.713 ± 16.0627104.243 ± 103.150234.069 ± 42.374633.294 ± 55.4258182.558 ± 188.4254390.568 ± 294.2189—80.414 ± 75.9675151.520 ± 116.0079
2 hours post-dose11.465 ± 8.7427107.729 ± 62.834337.782 ± 31.689074.626 ± 50.7053162.435 ± 161.8489426.804 ± 212.538513.973 ± 15.3652102.166 ± 78.0785101.618 ± 65.2415
4 hours post-dose6.647 ± 4.453375.907 ± 31.278620.122 ± 9.938351.005 ± 24.6435118.217 ± 42.0873188.383 ± 111.9267———
6 hours post-dose3.663 ± 3.406152.966 ± 29.029719.435 ± 15.725945.502 ± 17.895069.708 ± 44.3168125.279 ± 89.0005———
8 hours post-dose3.880 ± 3.3171—15.699 ± 20.759615.691 ± 15.1392—————
SecondaryAssessment of Ticagrelor Concentration - Part B
Time frame:
PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Reported as:
Geometric mean · ng/mL
Assessment of Ticagrelor Concentration - Part B
ng/mLTicagrelor 0.125 mg/kg Bid
Pre-dose2.478 ± 3.9580
1 hour post-dose9.677 ± 9.4275
2 hours post-dose14.144 ± 12.4711
4 hours post-dose9.605 ± 14.4979
SecondaryAssessment of AR-C124910XX Concentration - Part A

AR-C124910XX is the active metabolite of Ticagrelor

Time frame:
In conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7), after repeated dosing at Visit 4 (Day 14). Up to 8h post-dose (6h following protocol amendment, no pre-dose) Visit 2 and 3, up to 2h Visit 4 (pre-dose, 1h added following amendment)
Reported as:
Geometric mean · ng/mL
Assessment of AR-C124910XX Concentration - Part A
ng/mLTicagrelor 0.125 mg/kgTicagrelor 0.75 mg/kgTicagrelor 0.375 mg/kgTicagrelor 0.563 mg/kgTicagrelor 1.125 mg/kgTicagrelor 2.25 mg/kgTicagrelor 0.125 mg/kg BidTicagrelor 0.563 mg/kg BidTicagrelor 0.75 mg/kg Bid
Pre-dose——————1.250 ± NA17.380 ± 10.039920.359 ± 15.0788
1 hour post-dose1.782 ± 1.660416.302 ± 22.46144.577 ± 7.86103.708 ± 13.333230.070 ± 44.295063.088 ± 84.2091—24.945 ± 15.654743.986 ± 29.8127
2 hours post-dose2.681 ± 2.073333.256 ± 25.385411.757 ± 13.332215.918 ± 17.484952.932 ± 69.1056149.772 ± 71.36244.026 ± 4.762437.013 ± 32.765044.690 ± 31.6577
4 hours post-dose2.071 ± 1.277029.860 ± 13.87267.630 ± 6.373017.015 ± 7.927250.887 ± 25.6964101.370 ± 44.6207———
6 hours post-dose1.646 ± 1.042725.276 ± 10.83189.762 ± 2.330416.703 ± 5.811535.716 ± 22.335176.941 ± 39.9167———
8 hours post-dose1.715 ± 1.0226—6.176 ± 6.31689.232 ± 2.5385—————
SecondaryAssessment of AR-C124910XX Concentration - Part B

AR-C124910XX is the active metabolite of Ticagrelor

Time frame:
PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Reported as:
Geometric mean · ng/mL
Assessment of AR-C124910XX Concentration - Part B
ng/mLTicagrelor 0.125 mg/kg Bid
Pre-dose1.810 ± 1.1213
1 hour post-dose2.865 ± 1.6443
2 hours post-dose4.160 ± 3.1503
4 hours post-dose3.953 ± 4.1179
SecondaryOral Clearance (CL/F) - Part A

The PK parameter presented were derived using a model based analysis and not from a non-compartmental (NCA) analysis.

Time frame:
PK measurements (up to 8 hours post-dose) are taken in conjunction with single doses at Visit 2 (Day 0) and Visit 3 (Day 7) and after repeated dosing at Visit 4 (Day 14).
Reported as:
Geometric mean · L/h
Oral Clearance (CL/F) - Part A
L/hOverall
Oral Clearance (CL/F) - Part A22.50 ± 7.531
SecondaryOral Clearance (CL/F) - Part B

The PK parameter presented was derived using a model based analysis and not from a non-compartmental (NCA) analysis.

Time frame:
PK measurements (up to 4 hours post-dose) are taken after 4 weeks of double blind treatment at the end of Part B.
Reported as:
Geometric mean · L/h
Oral Clearance (CL/F) - Part B
L/hTicagrelor 0.125 mg/kg Bid
Oral Clearance (CL/F) - Part B19.15 ± 6.673
SecondaryNumber of Vaso-occlusive Crises - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Number of events
Number of Vaso-occlusive Crises - Part B
Number of eventsPart B - TicagrelorPart B - Placebo
Number of Vaso-occlusive Crises - Part B1.0 ± 2.000.6 ± 0.74
SecondaryNumber of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Number of events
Number of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B
Number of eventsPart B - TicagrelorPart B - Placebo
Number of Vaso-occlusive Crises Requiring Hospitalization or Emergency Department Visits - Part B0.2 ± 0.410.1 ± 0.35
SecondaryPercentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Percentage of days
Percentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B
Percentage of daysPart B - TicagrelorPart B - Placebo
Percentage of Days Hospitalized for Vaso-occlusice Crisis or Other Complications of Sickle Cell Disease - Part B4.52 ± 11.8161.34 ± 3.788
SecondaryPercentage of Days With Pain (Age >=4) - Part B

Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain

Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Percentage of days
Percentage of Days With Pain (Age >=4) - Part B
Percentage of daysPart B - TicagrelorPart B - Placebo
Percentage of Days With Pain (Age >=4) - Part B27.01 ± 34.06531.78 ± 23.731
SecondaryMean Intensity of Pain (Age >=4) - Part B

Pain measured using the Faces Pain Scale, range 0-10 (0, 2, 4, 6, 8, 10), where 0 is no pain

Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Mean score on scale
Mean Intensity of Pain (Age >=4) - Part B
Mean score on scalePart B - TicagrelorPart B - Placebo
Overall - Part B1.40 ± 2.0270.87 ± 0.493
1st week1.64 ± 2.6031.36 ± 0.827
2nd week1.11 ± 2.2360.38 ± 0.525
3rd week1.06 ± 1.8810.67 ± 1.116
4th week1.46 ± 2.6240.83 ± 0.901
SecondaryPercentage of Days of Analgesic Use (Age >= 4) - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Percentage of days
Percentage of Days of Analgesic Use (Age >= 4) - Part B
Percentage of daysPart B - TicagrelorPart B - Placebo
Percentage of Days of Analgesic Use (Age >= 4) - Part B16.79 ± 20.83818.56 ± 19.110
SecondaryPercentage of Days of Opioid Analgesic Use (Age >=4) - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Percentage of days
Percentage of Days of Opioid Analgesic Use (Age >=4) - Part B
Percentage of daysPart B - TicagrelorPart B - Placebo
Percentage of Days of Opioid Analgesic Use (Age >=4) - Part B12.46 ± 22.5020.54 ± 1.537
SecondaryPercentage of Days of Absence From School or Work (Age >=6) - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Mean · Percentage of days
Percentage of Days of Absence From School or Work (Age >=6) - Part B
Percentage of daysPart B - TicagrelorPart B - Placebo
Percentage of Days of Absence From School or Work (Age >=6) - Part B4.87 ± 10.8655.95 ± 9.494
Other pre-specifiedHaemorrhagic Events - Part A
Time frame:
From randomisation to Part A (week 0) through Visit 4 (week 2)
Reported as:
Number · Number of events
Haemorrhagic Events - Part A
Number of eventsPart A - Ticagrelor
Haemorrhagic Events - Part A0
Other pre-specifiedHaemorrhagic Events - Part B
Time frame:
During 4 weeks of study treatment starting from randomization in Part B (week 2) up to 4 weeks (week 6).
Reported as:
Number · Number of events
Haemorrhagic Events - Part B
Number of eventsPart B - TicagrelorPart B - Placebo
Haemorrhagic Events - Part B00

Adverse events

Collected over SAEs were collected from Visit 1 and AEs from Visit 2. SAEs and Other AEs are presented by study period, where Part A consists of the time from randomization to Part A through Visit 4. Part B starts the day after Visit 4 and continues until Visit 8.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Ticagrelor0/45 (0%)5/45 (11.1%)22/45 (48.9%)
Part B - Ticagrelor0/16 (0%)4/16 (25%)12/16 (75%)
Part B - Placebo0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Most frequent serious events
Most frequent serious events
EventPart A - TicagrelorPart B - TicagrelorPart B - Placebo
Sickle cell anemia with crisisBlood and lymphatic system disorders3/453/161/7
Acute chest syndromeRespiratory, thoracic and mediastinal disorders1/451/160/7
Gastroenteritis viralInfections and infestations1/450/160/7
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPart A - TicagrelorPart B - TicagrelorPart B - Placebo
Abdominal painGastrointestinal disorders6/453/162/7
ArthralgiaMusculoskeletal and connective tissue disorders5/454/162/7
Pain in extremityMusculoskeletal and connective tissue disorders5/453/162/7
HeadacheNervous system disorders4/450/162/7
VomitingGastrointestinal disorders0/453/160/7
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/453/160/7
Sickle cell anemia with crisisBlood and lymphatic system disorders6/451/161/7
GastritisGastrointestinal disorders0/450/161/7
Facial painGeneral disorders2/451/161/7
Non-cardiac chest painGeneral disorders2/451/161/7

Baseline characteristics

The baseline characteristics are tabulated by the actual treatment group. This differs from the numbers in the Participant Flow since not all randomised patients received IP and one patient receiving treatment not matching the randomised treatment

Age, Continuous
Age, Continuous(Years)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
Mean11.2 ± 3.34——11.2 ± 3.34
Age, Continuous
Age, Continuous(Years)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
Mean—10.2 ± 3.739.7 ± 3.3510.0 ± 3.55
Sex: Female, Male
Sex: Female, Male(Participants)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
Female240024
Male210021
Sex: Female, Male
Sex: Female, Male(Participants)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
Female09211
Male07512
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
Hispanic or Latino1001
Not Hispanic or Latino440044
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
Hispanic or Latino0101
Not Hispanic or Latino015722
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
White100010
Black or African American350035
Asian0000
Native Hawaiian or Other Pacific Islander0000
American Indian or Alaska Native0000
Other0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - TicagrelorPart B - TicagrelorPart B - PlaceboTotal
White0101
Black or African American015722
Asian0000
Native Hawaiian or Other Pacific Islander0000
American Indian or Alaska Native0000
Other0000
08

Study locations

18 sites
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Hershey, Pennsylvania 17022, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Research Site
    Kisian, 100, Kenya
  • Research Site
    Nairobi, Kenya
  • Research Site
    Beirut, 1107 2020, Lebanon
  • Research Site
    Beirut, 113-6044, Lebanon
  • Research Site
    Tripoli, 1434, Lebanon
  • Research Site
    Parow, 7500, South Africa
  • Research Site
    Rondebosch, 7700, South Africa
  • Research Site
    Cardiff, CF4 4XN, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    London, SE1 7EH, United Kingdom
  • Research Site
    Manchester, M13 9PT, United Kingdom
09

References and documents

Publications

  • Hsu LL, Sarnaik S, Williams S, Amilon C, Wissmar J, Berggren A; HESTIA1 Investigators. A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study. Am J Hematol. 2018 Dec;93(12):1493-1500. doi: 10.1002/ajh.25273. Epub 2018 Oct 2. PubMed 30187935 ↗
  • Amilon C, Niazi M, Berggren A, Astrand M, Hamren B. Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. Clin Pharmacokinet. 2019 Oct;58(10):1295-1307. doi: 10.1007/s40262-019-00758-0. PubMed 30972696 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Feb 2017, 29 months.

Results were first posted in May 2018, 1 year 2 months after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 29 months is close to that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2014
First posted
Aug 12, 2014
StartActual
Sep 11, 2014
Primary completionActual
Feb 27, 2017
CompletionActual
Feb 27, 2017
Results first posted
May 11, 2018
Last update
Dec 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02214121
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 12, 2014
Start date
Sep 11, 2014
Primary completion
Feb 27, 2017
Completion
Feb 27, 2017
Results posted
May 11, 2018
Last update
Dec 14, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion